Community Discussion
In our community we students of the market openly discuss our various market insights and thoughtful opinions in support of a wider understanding of price behavior. Join us and share your thoughts!
Latest Comments
Recent Posts
- Apple: Bottom Of 9th Inning November 19, 2019
- If Equities Drop, Just Add More November 18, 2019
- S&P 500 And 2015 November 11, 2019
- Not Trusting The A/D Line November 8, 2019
- Equity Markets Roll On Towards Euphoria November 6, 2019
- Alcoa: The Worst May Be Behind November 1, 2019
- Squaring Investor Pessimism And Equity Record Highs October 29, 2019
My Sage hedge is Axsome … pulled back some on Blueprint today.. negative action.. will watch trades close tomorrow.
Did add more Edit today. As Crsp is doing fantastic clinicals with Sickle Cell and TDT using ‘ ex-vivo ‘ Crispr cell treatment [cells taken outside the body, re-engineered, and then infused back in the body ] …. Editas is doing Crispr therapy with LCA 10 blindness using ‘ in-vivo ‘ editing [ inside the body ]. The LCA 10 trial is the first ever in-vivo crispr therapy in the US. If successful, the implications for this type of gene editing would be a quicker and more convenient procedure for the patient. Only time will tell, and Crispr Therapeutics will… Read more »
Maybe $ 90 – $ 110 , after looking at CMO & CEO options taken in September, 2019
Started Sage (after hours) … reminded that Prozac needed repeated attempts to get it right. Need to realize Sage’s first FDA approved ( in March ) ‘ Zulresso,’ although infusion, is still the gold standard and is light years faster in effectiveness than any other post-partum depression therapy available. Speed of efficacy is tremendously important in severe depression scenarios. Sage 217 will undergo new trials after discussions with FDA…If there was ever a positive buyout after bad news, Sage is it… As just a guess, I think $ 120.00…..
suncoke $5.45 up 6% today following b. riley upgrade. off its highs though.
https://finviz.com/quote.ashx?t=SXC&ty=c&ta=1&p=d
earning one month ago. “. . earnings of $0.13 per share on revenue of $404.3 million. The consensus earnings estimate was $0.09 per share on revenue of $359.1 million. Revenue grew 10.9% on a year-over-year basis.”
https://www.earningswhispers.com/epsdetails/sxc
https://finviz.com/quote.ashx?t=SXC&ty=c&ta=1&p=d
re buybacks: well put Bill
Possible cycle bottoming process of the Goldminers is near completion
Can stock buy-backs, done to increase earnings per share, go too far? Yes, agues this writer, if the company takes on too much debt, like Oracle. https://www.cnbc.com/2019/12/05/oracle-shows-buybacks-can-go-too-far.html However, if free cash flow is sufficient to combat the future impact of rising interest rates from currently historical low levels, I don’t see the problem as described by this writer. Now, share buy-backs, in general, I have a problem with for other reasons, particularly when treasury cash could be used for organic growth, accretive acquisitions and the like, and particularly when the tactic is part of an overall strategy to enrich a… Read more »
Nat Res back in the green, for now. Held in check by HBM.
Also, interesting Nat Gas futures over the past several months
eia natural gas: -19Bcf 591 Bcf higher than last year at this time and 9 Bcf below the five-year average.
http://ir.eia.gov/ngs/ngs.html
gm. dupont $61.93 at 52 week lows, post earnings oct. 31st it traded up to ~$72
https://www.earningswhispers.com/epsdetails/dd
https://finviz.com/quote.ashx?t=dd&ty=c&ta=1&p=d
the index has been down since early november: https://stockcharts.com/h-sc/ui?s=$DJUSCH
Baytex (BTE) announcement
https://seekingalpha.com/pr/17718942-baytex-announces-2020-budget-and-board-chair-appointment
Equity market is benefitting from capital being re-allocated from bonds to stocks as seen by the US 10-year Treasury yield on the rise this morning.
Selling in some sectors is on account of profit-taking after yesterday’s big move higher. For example, my Nat Res closed up +7% and is now down -1%. To be expected.
Day traders ought to stay focused on the 10-year Treasury yield.
Glencore (GLEN.L) is under pressure from both the US and UK now for corrupt activities. This is a candidate to avoid as these charges could be messy.
Ardelyx (ADRX) to issue 20 mil plus the option of 3 mil more for $6.25. This major development ought to strengthen the company’s foundation and give stakeholders more confidence in their future.
https://seekingalpha.com/news/3523885-ardelyx-prices-upsized-equity-offering
Opening today for Cannabis stocks ought to be strong across the board
You’re welcome, skyler. Scatter is good…. you will be processing a wealth of information from many, many locations… just remember to take notes…… and where you put them !! …. ** also, congratulations to Canada’s ‘ AUPH ‘ tonight… up 119 % after market.
* damn touchscreen…. ” if so, it really bodes well for their work together on Hepatitis B virus. “. A cure, not just remission or suppression…. if Institutional, probably won’t show up at SEC filings till next quarter updates ( sometime in January, 2020 ).
Wow …. after market… Dicerna ( DRNA ) had a 1,500,000 share block buy at $ 24.73, and a 500,000 share block buy at $ 24.75. These were the last two trades of the day at 5:58 PM and 5:59 pm….. No other trades afterward… appx. 67,000 shares had traded up to that point, at an average price of $ 26.90…. got to be institutional…. perhaps Roche bought another chunk of the company… if so., really bodies well ffg or th err or work on Hepatitis B th together,…
great baz22 was hoping you’d respond. btw your knowledge on these biotechs really requires alot
of study and reading. i’ve been trying recently it’s alot of work, though i have an advantage of being
scatter-brained ;D. anyways thankyou for keeping us apprized.
Good, full read on Ionis at Seeking Alpha tonight, before it’s relocated to ‘ subscription only ‘ ..